Venereology

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Retrieved on: 
Wednesday, April 10, 2024
Administration, Venereology, Inflammation, Mouse, Skin, Drug development, University Medical Center, CDMO, Patient, Concept, Psoriasis, I&I, Pharmaceutical industry

Their presentation will cover the use of Scinai's NanoAbs as a local treatment for plaque psoriasis.

Key Points: 
  • Their presentation will cover the use of Scinai's NanoAbs as a local treatment for plaque psoriasis.
  • In addition, Scinai's CEO, Mr. Amir Reichman will be panel participant in the panel discussion titled: "Route of Administration & Formulations: How Can We Improve?"
  • Scinai's Anti-IL-17A/F NanoAbs are designed to address large unmet therapeutic needs of mild to moderate plaque psoriasis patients.
  • Scinai is testing its anti-IL-17A/F nanoAb in a Proof of Concept in-vivo study in mice xenografted with human skin induced to express plaque psoriasis.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Retrieved on: 
Monday, March 4, 2024
MIRA, University College Dublin, Doctor of Philosophy, MD, Teaching hospital, Single-domain antibody, EST, Hidradenitis suppurativa, Inflammation, AAD, Safety, Patient, PST, Moonlake, Venereology, HS, American Academy, Pharmaceutical industry

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.

Key Points: 
  • Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.
  • The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
  • Key members of the MoonLake team, including the executive leadership team, will attend AAD.
  • This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.

BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake

Retrieved on: 
Thursday, December 7, 2023
Family, Risk, Johnson & Johnson, Aes, Infection, Q4, Physician, HCP, FDA, Thrombosis, RealTime, Venereology, JAK, BMS, Launch, Benchmarking, Patient, Safety, Psoriasis, TYK2, Malignancy, LTE, TYK, Pharmaceutical industry

There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.

Key Points: 
  • There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.
  • One participating dermatologist highlights, “even though it's not a direct JAK inhibitor, it still is in that same family.
  • Contact rates between BMS sales representatives and healthcare professionals have consistently increased, with the majority now reporting interactions with a Sotyktu representative since launch.
  • An influential factor in reshaping safety perceptions regarding the oral psoriasis treatment involves BMS’ ongoing long-term-extension (LTE) trial, known as POETYK.

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

Retrieved on: 
Monday, November 13, 2023
Safety, Therapy, SAD, Clinical trial, Sanofi, Fed, Patient, Inflammation, Pharmacokinetics, Atopic dermatitis, HS, Blood, Venereology, Biomarker, Hidradenitis suppurativa, Skin, Manuscript, TPD, Pharmaceutical industry, HV, IRAK4, Dermatology, Nature Medicine

WATERTOWN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that results from the positive Phase 1 clinical trial from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, were published in Nature Medicine. The results showed a reduction of disease-relevant inflammatory biomarkers in the blood and skin of HS and AD patients associated with improvement in skin lesions and symptoms. The full manuscript, “IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial,” was published online on November 13, 2023, on the Nature Medicine website.

Key Points: 
  • The results showed a reduction of disease-relevant inflammatory biomarkers in the blood and skin of HS and AD patients associated with improvement in skin lesions and symptoms.
  • The full manuscript, “IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial,” was published online on November 13, 2023, on the Nature Medicine website.
  • The Company previously reported Phase 1 results in December 2022 and at the European Academy of Dermatology and Venereology Symposium in May 2023.
  • The publication also highlights preclinical data on KT-474, including the first publication of the compound’s chemical structure.

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023
Diet, NAFLD, Three Months, Progression-free survival, Glioblastoma, Bevacizumab, AASLD, GBM, Clinical trial, Patient, Research, Liver, IPO, Abstract, R, Congress, FASN, Human, NASH, Acne, Fibrosis, Pharmaceutical industry, Medical imaging, Cryptocurrency, Boston, G&A, Venereology, Dermatology

SAN MATEO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

Key Points: 
  • Revenues for the third quarter ended September 30, 2023 were $2.0 million compared to no revenues for the third quarter of 2022.
  • Research and development (R&D) expense for the third quarter ended September 30, 2023 was $5.0 million compared to $6.8 million for the third quarter of 2022.
  • Net loss for the third quarter ended September 30, 2023 was $6.4 million compared to a net loss of $7.5 million for the third quarter of 2022.
  • The net loss for the nine months ended September 30, 2023 totaled $19.7 million compared to $23.3 million for the same period in 2022.

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
European Academy of Management, Safety, SAN, General counsel, Research and development, Therapy, IND, Initial public offering, Exercise, Clinical trial, Administration, Aulus Cornelius Cossus Arvina, Patient, TARC, G&A, Pharmacokinetics, Atopic dermatitis, Conference, IPO, Half-life, R, Growth, Chronic obstructive pulmonary disease, Congress, Health, I&I, Asthma, Inflammation, Vaccine, Pharmaceutical industry, COPD, Apsis, Venereology, Dermatology

SAN FRANCISCO and WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided business updates and reported third quarter 2023 financial results.

Key Points: 
  • “I am proud of our team’s execution during the third quarter and 2023 overall.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $17.1 million, compared to $9.9 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.2 million, compared to $0.6 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $20.8 million, compared to the net loss for the third quarter of 2022 which was $19.7 million.

Pusan National University Researchers Dive Deep Into the Safety of JAK Inhibitors for Atopic Dermatitis

Retrieved on: 
Friday, December 15, 2023
Janus, ClinicalTrials.gov, Itch, Associate, European Academy of Management, Research, Safety, Food, JAK, Incidence, US Foods, Headache, Risk, Meta-analysis, Patient, Shingles, Inflammation, Journal, Informatics, FDA, Coronary thrombosis, COVID-19, Atopic dermatitis, Isabella Tree, Nausea, Malignancy, Red, Swelling, Ankylosing spondylitis, Dermatology, Skin, Systematic review, Quality of life, Pusan National University, Health informatics, Acne, Pharmaceutical industry, MEDLINE, Anatomy, Embase, Venereology

In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.

Key Points: 
  • In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.
  • However, the FDA has also issued a boxed warning for JAK inhibitors to include the risk of major adverse events.
  • Since then, many meta-analyses focusing on the safety of JAK inhibitors have been published, but these analyses are fraught with several limitations.
  • Title of original paper: The safety of systemic Janus kinase inhibitors in atopic dermatitis:

Legacy Healthcare's Botanical Drug Candidate for the Treatment of Alopecia Areata in Children Highlighted in Multiple News Outlets

Retrieved on: 
Tuesday, November 21, 2023
Adolescence, Research, Conditional sentence, Inflammation, Advantage Business Media, Medscape, Radio, Authority, History, Patient, Alopecia areata, Harti, Q&A, Drug discovery, Interview, Development, Autoimmunity, Pharmaceutical industry, Dietary supplement, Venereology, Dermatology

LAUSANNE, Switzerland , Nov. 21, 2023 /PRNewswire/ -- Legacy Healthcare, a clinical-stage biopharmaceutical company developing transformative medicines for the treatment of autoimmune and inflammatory diseases, continues to be featured in news outlets highlighting the company's lead drug candidate, Coacillium, for the treatment of moderate and severe alopecia areata in children and adolescents.

Key Points: 
  • LAUSANNE, Switzerland , Nov. 21, 2023 /PRNewswire/ -- Legacy Healthcare, a clinical-stage biopharmaceutical company developing transformative medicines for the treatment of autoimmune and inflammatory diseases, continues to be featured in news outlets highlighting the company's lead drug candidate, Coacillium, for the treatment of moderate and severe alopecia areata in children and adolescents.
  • However, the placebo group stays relatively about the same range."
  • Drug Discovery & Development published the article "Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug" noting that the company believes Coacillium could be a blockbuster, given its promise as a treatment for alopecia areata.
  • Authority published an in-depth Q&A with Harti where he recalls the exact point in time when developing a first botanical drug became a clear objective.

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Molecule, Research, KIT, IND, Journal of the European Academy of Dermatology and Venereology, G&A, Inflammation, MAD, Cold urticaria, R, Pharmacokinetics, European Academy of Management, Medicine, Venereology, Safety, D, SAN, Pharmaceutical industry, Cryptocurrency, Patient, Dermatology

SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • On October 31, 2023, Third Harmonic Bio announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor effective November 1, 2023.
  • Additionally, the company announced that Robert Ho, Chief Financial Officer, is departing the organization on November 10, 2023.
  • R&D expenses for the nine months ended September 30, 2023 increased to $18.0 million, from $15.1 million for the same period in 2022.
  • G&A expenses for the nine months ended September 30, 2023 increased to $15.5 million, from $9.0 million for the same period in 2022.

Dermatologic Surgeons Recognized for Annual Awards at the 2023 ASDS Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Education, Inflammation, International, Medicare, History, MBA, ASDS, Organization, Health, Research, Cryomodule, Systematic review, Meta-analysis, Lecture, Society, Tribhuvan University Teaching Hospital, Medicine, Reduction, Surgeon, Partnership, CAE, Samuel, Melanoma, Chester L. Krause Memorial Distinguished Service Award, Amputation, Associate, Veterinary medicine, Dentistry, Management, Nursing, Dermatology, MD, MBBS, Pain, DRS, Venereology

Schaumburg, IL, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elite dermatologists were recognized during the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago, Illinois, for a variety of annual service awards, competitions and program recognitions.

Key Points: 
  • Schaumburg, IL, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elite dermatologists were recognized during the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago, Illinois, for a variety of annual service awards, competitions and program recognitions.
  • The Society’s annual awards acknowledge their outstanding work and commitment to the dermatologic surgery specialty.
  • Dr. Butterwick was recognized at the 16th Annual ASDS Gala on Saturday, Nov. 4.
  • The 2023 grant recipients are:
    The ASDS Journal Awards Work Group reviews program applications to identify those that exceptionally evaluate existing works.